These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 20373871)

  • 21. PIM kinase (and Akt) biology and signaling in tumors.
    Warfel NA; Kraft AS
    Pharmacol Ther; 2015 Jul; 151():41-9. PubMed ID: 25749412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting FGFR Signaling in Cancer.
    Touat M; Ileana E; Postel-Vinay S; André F; Soria JC
    Clin Cancer Res; 2015 Jun; 21(12):2684-94. PubMed ID: 26078430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Autophagy, new perspectives in anticancer therapy].
    Lisiak N; Totoń E; Rybczyńska M
    Postepy Hig Med Dosw (Online); 2014; 68():925-35. PubMed ID: 24988612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nitric oxide: Protein tyrosine phosphorylation and protein S-nitrosylation in cancer.
    Monteiro HP; Costa PE; Reis AK; Stern A
    Biomed J; 2015; 38(5):380-8. PubMed ID: 26068128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Role of Grb2 in Cancer and Peptides as Grb2 Antagonists.
    Ijaz M; Wang F; Shahbaz M; Jiang W; Fathy AH; Nesa EU
    Protein Pept Lett; 2018 Feb; 24(12):1084-1095. PubMed ID: 29173143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extracellular vesicle communication pathways as regulatory targets of oncogenic transformation.
    Choi D; Lee TH; Spinelli C; Chennakrishnaiah S; D'Asti E; Rak J
    Semin Cell Dev Biol; 2017 Jul; 67():11-22. PubMed ID: 28077296
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular biology of oncogenic inflammatory processes. I. Non-oncogenic and oncogenic pathogens, intrinsic inflammatory reactions without pathogens, and microRNA/DNA interactions (Review).
    Sinkovics JG
    Int J Oncol; 2012 Feb; 40(2):305-49. PubMed ID: 22076306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The TRAIL of oncogenes to apoptosis.
    Oikonomou E; Pintzas A
    Biofactors; 2013; 39(4):343-54. PubMed ID: 23813857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibitors of phospholipid intracellular signaling as antiproliferative agents.
    Powis G; Hill SR; Frew TJ; Sherrill KW
    Med Res Rev; 1995 Mar; 15(2):121-38. PubMed ID: 7739293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis.
    Porter AC; Vaillancourt RR
    Oncogene; 1998 Sep; 17(11 Reviews):1343-52. PubMed ID: 9779982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The sensitivity to Hsp90 inhibitors of both normal and oncogenically transformed cells is determined by the equilibrium between cellular quiescence and activity.
    Echeverria PC; Bhattacharya K; Joshi A; Wang T; Picard D
    PLoS One; 2019; 14(2):e0208287. PubMed ID: 30726209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-diabetic drug metformin: challenges and perspectives for cancer therapy.
    Snima KS; Pillai P; Cherian AM; Nair SV; Lakshmanan VK
    Curr Cancer Drug Targets; 2014; 14(8):727-36. PubMed ID: 25329671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic Targeting of Oncogenic Tyrosine Phosphatases.
    Frankson R; Yu ZH; Bai Y; Li Q; Zhang RY; Zhang ZY
    Cancer Res; 2017 Nov; 77(21):5701-5705. PubMed ID: 28855209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The oncogenic neurotrophin receptor tropomyosin-related kinase variant, TrkAIII.
    Farina AR; Cappabianca L; Ruggeri P; Gneo L; Pellegrini C; Fargnoli MC; Mackay AR
    J Exp Clin Cancer Res; 2018 Jun; 37(1):119. PubMed ID: 29914559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy.
    Wierstra I
    Adv Cancer Res; 2013; 119():191-419. PubMed ID: 23870513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of Pin1 in the development and treatment of cancer.
    Min SH; Zhou XZ; Lu KP
    Arch Pharm Res; 2016 Dec; 39(12):1609-1620. PubMed ID: 27572155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vitamin C as an Anticancer Agent: Regulation of Signaling Pathways.
    Butt G; Farooqi AA; Adylova A; Attar R; Yilmaz S; Konysbayevna KK; Sabitaliyevich UY; Gasparri ML; Xu B
    Curr Top Med Chem; 2020; 20(21):1868-1875. PubMed ID: 32648842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Drug resistance mediated by survival- and growth-promoting signaling pathways].
    Fujita N
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):567-71. PubMed ID: 19381028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting Oncogenic Nuclear Factor Kappa B Signaling with Redox-Active Agents for Cancer Treatment.
    Fouani L; Kovacevic Z; Richardson DR
    Antioxid Redox Signal; 2019 Mar; 30(8):1096-1123. PubMed ID: 29161883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.